Loading…
MediciNova, Inc. is projected to rise to $1.48 by 2027, a +7% move from its current price of $1.39. MNOV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.36 | $1.39 | $1.42 | +0.02% |
| Jul 14 | $1.35 | $1.39 | $1.43 | +0.04% |
| Jul 15 | $1.34 | $1.39 | $1.44 | +0.06% |
| Jul 16 | $1.34 | $1.39 | $1.45 | +0.08% |
| Jul 17 | $1.33 | $1.39 | $1.46 | +0.10% |
| Jul 18 | $1.32 | $1.39 | $1.46 | +0.12% |
| Jul 19 | $1.32 | $1.39 | $1.47 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.32 | $1.39 | $1.47 | +0.14% |
| Week 2 | $1.29 | $1.39 | $1.50 | +0.28% |
| Week 3 | $1.27 | $1.40 | $1.53 | +0.42% |
| Week 4 | $1.26 | $1.40 | $1.55 | +0.56% |
| Week 5 | $1.24 | $1.40 | $1.58 | +0.70% |
| Week 6 | $1.23 | $1.40 | $1.60 | +0.84% |
| Week 7 | $1.22 | $1.40 | $1.62 | +0.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MediciNova, Inc. is a biopharmaceutical company focused on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
MNOV is currently trading at $1.42.
It ranks 4432 and has a market cap of $69.89M.
The multi-year forecast shows an upward path, with 2026 avg price at $1.42 and 2050 avg price at $8.10, and a 2050 max price of $14.09.
The forecast also indicates rising averages beyond 2026, with 2030 avg $2.19 and 2040 avg $4.04 supporting a long-run upside trajectory.
A major floor 17.7% below — a decisive break under it would weaken the trend.
The nearest floor, 11.5% below — buyers have tended to step in here.
The nearest ceiling, 3.6% above — a clean break opens room to run.
A major ceiling 12.5% above — clearing it would confirm fresh momentum.
Key MNOV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MNOV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.41 | Sell | $1.40 | Sell |
| MA 10 | $1.39 | Buy | $1.38 | Buy |
| MA 20 | $1.34 | Buy | $1.37 | Buy |
| MA 50 | $1.36 | Buy | $1.37 | Buy |
| MA 100 | $1.39 | Sell | $1.39 | Buy |
| MA 200 | $1.42 | Sell | $1.41 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.72 | Neutral |
| Stoch RSI (14) | 50.70 | Neutral |
| CCI (20) | 60.37 | Neutral |
| Williams %R (14) | -35.71 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 2.21 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 64.29 | Neutral |
| TRIX (15) | 0.09 | Buy |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 63.71 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 1.40 | Sell |
| ADX (14) | 14.16 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is bullish. RSI14 is 60. The price sits above the SMA50 of $1.35 and near the SMA200 of $1.41. Support is at $1.23 and resistance at $1.42. The 30-day range runs from $1.22 to $1.65.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.23 | $1.39 | $1.75 | 0% | Neutral | |
| $1.21 | $1.48 | $1.90 | +7% | Neutral | |
| $1.25 | $1.57 | $2.07 | +13% | Neutral | |
| $1.47 | $1.87 | $2.52 | +34% | Bullish | |
| $1.68 | $2.17 | $2.99 | +56% | Bullish | |
| $1.79 | $2.34 | $3.27 | +68% | Bullish | |
| $1.84 | $2.43 | $3.46 | +75% | Bullish | |
| $1.87 | $2.51 | $3.61 | +80% | Bullish | |
| $2.02 | $2.73 | $3.98 | +96% | Bullish | |
| $2.16 | $2.95 | $4.35 | +112% | Bullish | |
| $2.91 | $4.17 | $6.46 | +200% | Bullish | |
| $5.42 | $8.37 | $13.95 | +502% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.23 | $1.39 | $1.67 | +0.00% |
| August 2026 | $1.20 | $1.40 | $1.68 | +0.90% |
| September 2026 | $1.20 | $1.42 | $1.71 | +0.93% |
| October 2026 | $1.23 | $1.46 | $1.78 | +3.20% |
| November 2026 | $1.23 | $1.46 | $1.79 | -0.12% |
| December 2026 | $1.19 | $1.42 | $1.75 | -2.64% |
Click any year to see its month-by-month MNOV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MNOV is projected to trade between $1.23 and $1.75, averaging $1.39 — a potential gain of 0% from today's $1.39. A consolidation phase looks the most probable path here.
MediciNova, Inc.'s 2027 outlook centres on $1.48, within a $1.21 to $1.90 range. That is up +7% on the projected 2026 average. That marks a +7% change versus current levels. Price action looks broadly range-bound.
By 2028, MNOV could reach as high as $2.07, with a base case around $1.57 and support toward $1.25 — roughly +13% from $1.39. A consolidation phase looks the most probable path here.
Expect MNOV to range from $1.47 to $2.52 through 2029. The $1.87 average target implies a +34% move from current prices. That is up +19% on the projected 2028 average. Momentum favours further upside here.
The MNOV price prediction for 2030 points to an average of $2.17 (low $1.68, high $2.99) — a potential gain of +56% on today's $1.39. Buyers look set to stay in control over this stretch.
In 2031, MNOV is projected to trade between $1.79 and $3.27, averaging $2.34 — a potential gain of +68% from today's $1.39. That is up +8% on the projected 2030 average. Momentum favours further upside here.
MediciNova, Inc.'s 2032 outlook centres on $2.43, within a $1.84 to $3.46 range. That is up +4% on the projected 2031 average. That marks a +75% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MNOV could reach as high as $3.61, with a base case around $2.51 and support toward $1.87 — roughly +80% from $1.39. Momentum favours further upside here.
Expect MNOV to range from $2.02 to $3.98 through 2034. The $2.73 average target implies a +96% move from current prices. That is up +9% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MNOV price prediction for 2035 points to an average of $2.95 (low $2.16, high $4.35) — a potential gain of +112% on today's $1.39. Momentum favours further upside here.
In 2040, MNOV is projected to trade between $2.91 and $6.46, averaging $4.17 — a potential gain of +200% from today's $1.39. That is up +41% on the projected 2035 average. Buyers look set to stay in control over this stretch.
MediciNova, Inc.'s 2050 outlook centres on $8.37, within a $5.42 to $13.95 range. That is up +101% on the projected 2040 average. That marks a +502% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MNOV today (≈ 719.42446 MNOV) could be worth
$6,020.37
+$5,020.37 (+502%) by 2050 · US Dollar
Based on the average projected MNOV price of $8.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MNOVwould be worth at today's price.
$1,000 invested in MNOV on Jul 10, 2025 (≈ 787.401587 MNOV) would be worth
$1,094.49
+$94.49 (+9.4%) today · 1.09× · US Dollar
Based on a MNOV entry price of $1.27 vs. today's $1.39.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.43 | $972.03 | -2.8% |
| 1 month ago | $1.27 | $1,094.49 | +9.4% |
| 3 months ago | $1.49 | $932.89 | -6.7% |
| 6 months ago | $1.44 | $965.28 | -3.5% |
| 1 year ago | $1.27 | $1,094.49 | +9.4% |
| All time (5.0y) ago | $3.74 | $371.66 | -62.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MNOV forecast.
Our base-case forecast reaches $2.80 around 2035.
Implied market cap at $2.80: $137.82M
The long-term forecast shows a bullish trajectory across the years. The 2029 forecast is avg $1.87 with ROI 32 and sentiment BULLISH, continuing through 2030 with avg $2.19 and ROI 54.4, and through 2031-2035 with rising averages (2031 $2.31, 2032 $2.43, 2033 $2.50, 2034 $2.65, 2035 $2.90) and corresponding ROIs (62.7, 70.8, 76.3, 86.7, 104.4) while remaining BULLISH.
By 2040 the forecast shows avg $4.04 with ROI 184.7 and sentiment BULLISH, and by 2050 avg $8.10 with ROI 470.3 and sentiment BULLISH, with a max forecast of $14.09 and a min forecast of $4.99 in 2050.
Tap a question to reveal the answer.
2030 forecast: min $1.67, avg $2.19, max $3.09; ROI 54.4; sentiment BULLISH.
The forecast shows rising averages and bullish sentiment in later years, with ROI reaching 32 in 2029, 54.4 in 2030, 62.7 in 2031, 70.8 in 2032, 76.3 in 2033, 86.7 in 2034, 104.4 in 2035, 184.7 in 2040, and 470.3 in 2050.
Yes, the forecast max in 2050 is $14.09, and the max in 2040 is $6.49, so a $10 target is within the forecast by 2050.
Current price is $1.42 and market cap is $69.89M. It ranks 4432.
2040 max: $6.49.
MediciNova, Inc. Community Discussion
0Share your MediciNova, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.